Vertex says FDA expands Casgevy approval to sickle cell, beta thalassemia patients age 2+
PUBT · 3d ago
Share
Listen to the news
- FDA cleared expanded use of Vertex’s CASGEVY for sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia in patients ages 2+.
- Decision makes CASGEVY the first approved genetic therapy for both conditions in children as young as 2 years.
- Vertex cited more than 75 activated authorized treatment centers in the U.S. to deliver the therapy through existing reimbursement pathways.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260701379449) on July 01, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved